Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14028 · 1 trial · 1 indication
Maximum (peak) plasma drug concentration
The area under the plasma concentration curve from 0 to ∞
| Arm | Type | Description |
|---|---|---|
| 14028 injection | EXPERIMENTAL | Subjects receive 14028 injection in the study, 0.75mg, once |
| dulaglutide injection (TRULICITY®) | ACTIVE_COMPARATOR | Subjects receive dulaglutide injection (TRULICITY®) in the study, 0.75mg, once |
| Name | Type | Description |
|---|---|---|
| 14028 injection | BIOLOGICAL | 14028 injection, single dose, s.c. injection |
| dulaglutide injection | BIOLOGICAL | dulaglutide injection(TRULICITY®), single dose, s.c. injection |
Inclusion Criteria: 1. Sign the informed consent form before the trial, understand and comply with the research process, and participate the trial voluntarily 2. Healthy male subjects aged 18 to 45 (including the critical value) 3. Weight \> or = 50 kg, and 19.0 kg/m2 \< or = BMI (body mass index) ...
Top 16 of 30 competitors
14028 is an investigational monoclonal antibody being developed for Type 2 Diabetes. It is currently in Phase 1 clinical development and has completed one trial in healthy Chinese subjects. The drug is not approved and remains under investigation.
14028 is a monoclonal antibody, but its specific molecular target has not been disclosed in available information. The drug is being studied for its pharmacokinetic profile in comparison to an active control in healthy subjects.
14028 is being developed by Sunshine Biopharma Inc., a company listed on the stock exchange under the ticker SBFM. The company is conducting clinical research on this investigational drug for Type 2 Diabetes.
14028 is in Phase 1 clinical development. It has completed one Phase 1 trial, and no active trials are currently listed. The drug remains investigational and has not been approved for any use.
14028 has been studied in one completed Phase 1 trial, NCT05459285, titled 'A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects.' The trial enrolled 68 healthy male participants in China and was active-controlled.
No, 14028 is not the same as TRULICITY. In the clinical trial NCT05459285, 14028 was compared against TRULICITY as an active control. TRULICITY is a separate, approved medication, while 14028 is an investigational monoclonal antibody.